Schroder Investment Management Group
SLNO

Schroder Investment Management Group’s Soleno Therapeutics SLNO Stock Holding History

Schroder Investment Management Group’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-648,827
Closed -$19.8M – 1241
2026
Q1 		$19.8M Buy
648,827
+198,979
+44% +$7.8M 0.02% 536
2025
Q4 		$20.8M Buy
449,848
+169,552
+60% +$9.3M 0.02% 501
2025
Q3 		$19.1M Buy
280,296
+263,359
+1,555% +$19.5M 0.01% 536
2025
Q2 		$1.42M Buy
+16,937
New +$1.27M ﹤0.01% 957

Schroder Investment Management Group's SLNO Position: Q2 2026 in Review

Schroder Investment Management Group sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 648,827 shares — an estimated $19.8M sold.

Schroder Investment Management Group first reported a position in SLNO in Q2 2025 and held it in 4 quarters. The position peaked at $20.8M in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

  • Schroder Investment Management Group reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Schroder Investment Management Group sold 648,827 Soleno Therapeutics shares in Q2 2026, an estimated $19.8M.
  • Schroder Investment Management Group first reported a position in Soleno Therapeutics in Q2 2025 and held it in 4 quarters.
  • Schroder Investment Management Group's Soleno Therapeutics position peaked at $20.8M in Q4 2025.
  • 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Schroder Investment Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.